Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO ® (blinatumomab) Label

BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy THOUSAND OAKS, Calif., June 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted a full marketing authorization for BLINCYTO® (blinatumomab) based on the overall survival (OS) data from the Phase 3 TOWER study in adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). "BLINCYTO is the first single agent immunotherapy to demonstrate superior overall survival benefit over standard of care," said David M. Reese, M.D., senior vice president of Translati...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news